scispace - formally typeset
S

Susana Liu

Researcher at Merck & Co.

Publications -  19
Citations -  908

Susana Liu is an academic researcher from Merck & Co.. The author has contributed to research in topics: Renin–angiotensin system & Renin inhibitor. The author has an hindex of 12, co-authored 17 publications receiving 873 citations.

Papers
More filters
Journal ArticleDOI

Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis

TL;DR: Findings strongly support the hypothesis that inhibition of PDE4D is pivotal to the anesthesia-reversing effect of PMNPQ and is likely responsible for emesis induced by PDE 4 inhibitors.
Journal ArticleDOI

Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets.

TL;DR: The results suggest that the cPLA2 plays an important role in the generation of free AA for 12-HETE biosynthesis in platelets and affects the cyclooxygenase pathway in addition to AA release.
Journal ArticleDOI

Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor

TL;DR: It is shown that specific inhibition of PDE4 preferentially blocks the production of Th1 versus Th2 effector cytokines in vitro and rolipram and L-826,141 are potent inhibitors of CD3-plus CD28-stimulated IL-2 production in naive human T cells.
Journal ArticleDOI

Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors

TL;DR: The activation of CFTR-mediated chloride secretion by phosphodiesterase (PDE) 4 inhibitors in T84 monolayer using 125I anion as tracer suggests that PDE3 and PDE4 form the major cAMP diffusion barrier in T 84 cells to ensure a compartmentalized CFTR signaling.
Journal ArticleDOI

Preferential inhibition of human phosphodiesterase 4 by ibudilast

TL;DR: The attenuated inflammatory and allergic responses from the potent and preferential PDE4 inhibition of ibudilast may have contributed significantly to its beneficial pharmacological responses and distinguishes ibudILast from the other ophthalmic solutions in the treatment of ocular allergy.